Trials / Completed
CompletedNCT02112838
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Rigel Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib 150 mg | Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks |
| DRUG | Fostamatinib 100 mg | Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks |
| DRUG | Placebo | Placebo tablet twice daily by mouth, over the course of 24 weeks |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2018-03-23
- Completion
- 2018-11-12
- First posted
- 2014-04-14
- Last updated
- 2019-06-27
- Results posted
- 2019-06-27
Locations
20 sites across 6 countries: United States, Austria, Germany, Hong Kong, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02112838. Inclusion in this directory is not an endorsement.